AU2017358289C1 - Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins - Google Patents

Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins Download PDF

Info

Publication number
AU2017358289C1
AU2017358289C1 AU2017358289A AU2017358289A AU2017358289C1 AU 2017358289 C1 AU2017358289 C1 AU 2017358289C1 AU 2017358289 A AU2017358289 A AU 2017358289A AU 2017358289 A AU2017358289 A AU 2017358289A AU 2017358289 C1 AU2017358289 C1 AU 2017358289C1
Authority
AU
Australia
Prior art keywords
protein
fgf21
amino acid
terminus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017358289A
Other languages
English (en)
Other versions
AU2017358289B2 (en
AU2017358289A1 (en
Inventor
Hyun Ho Choi
Han Na Hong
Dohoon Kim
Jong Gyun Kim
Jun Hwan Kim
Taewang Kim
Se Woong Oh
Moo Young Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of AU2017358289A1 publication Critical patent/AU2017358289A1/en
Publication of AU2017358289B2 publication Critical patent/AU2017358289B2/en
Priority to AU2025201790A priority Critical patent/AU2025201790A1/en
Application granted granted Critical
Publication of AU2017358289C1 publication Critical patent/AU2017358289C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017358289A 2016-11-10 2017-11-10 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins Active AU2017358289C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201790A AU2025201790A1 (en) 2016-11-10 2025-03-12 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0149866 2016-11-10
KR20160149866 2016-11-10
PCT/KR2017/012726 WO2018088838A1 (en) 2016-11-10 2017-11-10 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201790A Division AU2025201790A1 (en) 2016-11-10 2025-03-12 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

Publications (3)

Publication Number Publication Date
AU2017358289A1 AU2017358289A1 (en) 2019-06-20
AU2017358289B2 AU2017358289B2 (en) 2024-12-19
AU2017358289C1 true AU2017358289C1 (en) 2025-05-08

Family

ID=62110477

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017358289A Active AU2017358289C1 (en) 2016-11-10 2017-11-10 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
AU2025201790A Pending AU2025201790A1 (en) 2016-11-10 2025-03-12 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201790A Pending AU2025201790A1 (en) 2016-11-10 2025-03-12 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

Country Status (15)

Country Link
US (1) US11179440B2 (enExample)
EP (1) EP3568149B1 (enExample)
JP (3) JP7328891B2 (enExample)
KR (1) KR102692516B1 (enExample)
CN (1) CN110121355B (enExample)
AU (2) AU2017358289C1 (enExample)
BR (1) BR112019009581A2 (enExample)
CA (1) CA3042512A1 (enExample)
ES (1) ES3023833T3 (enExample)
HU (1) HUE071618T2 (enExample)
MX (1) MX2019005380A (enExample)
NZ (1) NZ752661A (enExample)
PL (1) PL3568149T3 (enExample)
WO (1) WO2018088838A1 (enExample)
ZA (1) ZA201903306B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
JP7191850B2 (ja) 2017-04-21 2022-12-19 ユーハン・コーポレイション デュアル機能タンパク質およびその誘導体を生産するための方法
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR20230034357A (ko) * 2020-07-02 2023-03-09 사노피 Glp-1r 작용제/fgf21 융합 단백질
KR20240034235A (ko) 2021-07-14 2024-03-13 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 대사 장애를 위한 융합 폴리펩타이드
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
KR20250039300A (ko) * 2023-09-11 2025-03-20 서울대학교병원 안지오포이에틴-1 융합 단백질 및 이의 용도
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129600A2 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2011020319A1 (zh) * 2009-08-20 2011-02-24 重庆富进生物医药有限公司 调节血糖血脂的融合蛋白及其制备方法和应用
CN102558358A (zh) * 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013188181A1 (en) * 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 proteins
US20140243503A1 (en) * 2008-06-04 2014-08-28 Amgen Inc. Fgf21 mutants and uses thereof
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
CN105288592A (zh) * 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
US9434778B2 (en) * 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
WO2017074117A1 (en) * 2015-10-28 2017-05-04 Yuhan Corporation Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
WO2017074123A1 (en) * 2015-10-28 2017-05-04 Yuhan Corporation Dual function proteins and pharmaceutical composition comprising same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
JP2006094727A (ja) * 2004-09-28 2006-04-13 Masaki Kamakura 細胞増殖促進作用及び器官再生促進作用を有すポリペプチドをコードする遺伝子
EP2126106B1 (en) 2007-02-23 2017-09-06 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
CN101732715B (zh) * 2008-11-07 2012-02-15 中国人民解放军军事医学科学院放射与辐射医学研究所 LSECtin及其融合蛋白在制备抑制癌细胞向肝转移药物中的应用
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
PL2393828T3 (pl) 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
CN102802657A (zh) 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
ES2543634T3 (es) 2010-01-22 2015-08-20 Novo Nordisk A/S Proceso para preparación de FGF-21 con grado de O-glicosilación bajo
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
CN102370686B (zh) * 2010-08-26 2013-09-18 上海中医药大学附属曙光医院 治疗慢性肝病的药物组合物及其应用
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US20140213512A1 (en) 2011-08-31 2014-07-31 Amgen Inc. Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
CN103860565B (zh) * 2012-12-10 2017-05-17 中国人民解放军军事医学科学院毒物药物研究所 一种治疗肝纤维化的药物组合物
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
WO2016048995A2 (en) * 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf19 truncations and mutants and uses thereof
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
JP7181886B2 (ja) * 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
JP7191850B2 (ja) 2017-04-21 2022-12-19 ユーハン・コーポレイション デュアル機能タンパク質およびその誘導体を生産するための方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140243503A1 (en) * 2008-06-04 2014-08-28 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2011020319A1 (zh) * 2009-08-20 2011-02-24 重庆富进生物医药有限公司 调节血糖血脂的融合蛋白及其制备方法和应用
US20120238496A1 (en) * 2009-08-20 2012-09-20 Chongqing Fagen Biomedical Inc. Fusion protein regulating plasma glucose and lipid, its preparation method and use
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
CN102558358A (zh) * 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
WO2013188181A1 (en) * 2012-06-11 2013-12-19 Eli Lilly And Company Fibroblast growth factor 21 proteins
US9434778B2 (en) * 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
WO2017074117A1 (en) * 2015-10-28 2017-05-04 Yuhan Corporation Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
WO2017074123A1 (en) * 2015-10-28 2017-05-04 Yuhan Corporation Dual function proteins and pharmaceutical composition comprising same
CN105288592A (zh) * 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hecht, R. et al., 'Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes', PLOS One, (2012), vol. 7, no. 11, e49345, pp. 1-14, doi: 10.1371/journal.pone.0049345. *
Kahal, H. et al., 'Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease', Clinical Endocrinology, (2014), vol. 81, pages 523 - 528. *
Schumacher, J. and Gui. G., 'Regulation of hepatic stellate cells and fibrogenesis by fibroblast growth factors', BioMed Research International, (2016-01-01), vol. 2016, pages 1 - 8, doi: 10.1155/2016/8323747. *

Also Published As

Publication number Publication date
EP3568149A1 (en) 2019-11-20
KR20180052545A (ko) 2018-05-18
CN110121355A (zh) 2019-08-13
RU2019117767A3 (enExample) 2021-01-28
WO2018088838A1 (en) 2018-05-17
AU2017358289B2 (en) 2024-12-19
EP3568149B1 (en) 2025-03-12
US11179440B2 (en) 2021-11-23
AU2017358289A1 (en) 2019-06-20
KR102692516B1 (ko) 2024-08-08
JP2020502053A (ja) 2020-01-23
JP2025114622A (ja) 2025-08-05
MX2019005380A (es) 2019-08-12
ES3023833T3 (en) 2025-06-03
EP3568149A4 (en) 2020-07-22
JP7328891B2 (ja) 2023-08-17
BR112019009581A2 (pt) 2019-10-08
CA3042512A1 (en) 2018-05-17
CN110121355B (zh) 2023-09-12
RU2019117767A (ru) 2020-12-10
AU2025201790A1 (en) 2025-04-03
HUE071618T2 (hu) 2025-09-28
ZA201903306B (en) 2020-09-30
NZ752661A (en) 2025-10-31
EP3568149C0 (en) 2025-03-12
US20190314452A1 (en) 2019-10-17
PL3568149T3 (pl) 2025-07-07
JP2023002571A (ja) 2023-01-10

Similar Documents

Publication Publication Date Title
US20250270269A1 (en) Dual function proteins comprising fgf21 mutant protein and pharmaceutical composition comprising same
AU2017358289C1 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
US20240279296A1 (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
NZ794313A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
RU2795548C2 (ru) Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки
NZ794312A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
HK40040781B (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
HK40040781A (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
HK40012348A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
HK40012348B (zh) 用於预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 DEC 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 12 DEC 2024

FGA Letters patent sealed or granted (standard patent)